Across TCGA pan-cancer cohorts, PTMA mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PTMA data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PTMA mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PTMA expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

HNSC, UCEC, and PDAC are the cancer types where PTMA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	II,III,IV	0.672	0.878	.009	16	view →
UCEC	DFS	Median	All	1.000	0.936	.023	10	view →
PDAC	OS	Median	III,IV	0.944	0.588	.006	10	view →
CCRCC	DFS	Tertile	III,IV	0.854	0.454	.013	4	view →
LSCC	OS	Quartile	All	0.923	0.777	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: PTMA tumor-vs-normal RNA expression · all PTMA data types